anagrelide

The drug is used to treat thrombocythemia in patients with myeloproliferative disorders. Its purpose is to reduce the number of platelets in the blood, lower the risk of thrombosis, and limit associated symptoms, such as thrombohemorrhagic phenomena.

Form: capsules

ATC: L01XX35

Manufacturer: Pharmasciences Inc.

The drug is intended to reduce platelet levels in patients at high risk of developing essential thrombocythemia if current treatment is ineffective or not tolerated by the patient.

Form: capsules, hard

ATC: L01XX35

Manufacturer: Sintón Hispania, S.L. (manufacturing "in bulk", primary and secondary packaging, physicochemical testing, responsible for batch release)

The drug is intended to reduce platelet levels in patients at high risk of developing essential thrombocythemia if other treatment methods are ineffective or not tolerated by the body.

Form: capsules, hard

ATC: L01XX35

Manufacturer: Sintón Hispania, S.L. (manufacturing "in bulk", primary and secondary packaging, physicochemical testing, responsible for batch release)

The drug is intended to reduce elevated platelet levels in patients at high risk of developing essential thrombocythemia if current treatment is ineffective or not tolerated by the patient.

Form: capsules, hard

ATC: L01XX35

Manufacturer: Synthon BV (batch release)

The drug is intended to reduce elevated platelet levels in patients at high risk of developing essential thrombocythemia if current treatment is ineffective or not tolerated by the patient.

Form: capsules, hard

ATC: L01XX35

Manufacturer: Synthon Hispania, S.L. (manufacturing of finished dosage form, primary and secondary packaging, physico-chemical batch control, batch release)